Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prevention of the Meningococcal Disease”

35 trials

Showing 20 of 35 results

Large-scale testing (Phase 3)Study completedNCT01423084
What this trial is testing

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis 344
Post-approval studies (Phase 4)Study completedNCT00271479
What this trial is testing

Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine

Who this might be right for
Infections, MeningococcalMeningitis, Meningococcic
Epicentre 720
Testing effectiveness (Phase 2)Study completedNCT00262028
What this trial is testing

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

Who this might be right for
Prevention of Meningococcal Disease
Novartis Vaccines 910
Large-scale testing (Phase 3)Study completedNCT01139021
What this trial is testing

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Who this might be right for
Meningococcal Disease
Novartis Vaccines 508
Post-approval studies (Phase 4)Study completedNCT00310635
What this trial is testing

Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

Who this might be right for
Meningococcal Infection
Novartis 241
Large-scale testing (Phase 3)Study completedNCT00847145
What this trial is testing

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Who this might be right for
Meningococcal Disease
Novartis Vaccines 2,249
Post-approval studies (Phase 4)Study completedNCT00316654
What this trial is testing

Persistence of Antibody Response to N. Meningitidis Group C in Children

Who this might be right for
Prevention of Meningococcal Infection
Novartis Vaccines 489
Testing effectiveness (Phase 2)Study completedNCT01027351
What this trial is testing

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

Who this might be right for
Meningococcal Disease
Novartis Vaccines 163
Post-approval studies (Phase 4)Study completedNCT02724046
What this trial is testing

Ciprofloxacin for the Prevention of Meningococcal Meningitis

Who this might be right for
Meningitis, Meningococcal
Epicentre 300
Testing effectiveness (Phase 2)Study completedNCT00381615
What this trial is testing

Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Who this might be right for
Healthy
Novartis Vaccines 147
Testing effectiveness (Phase 2)Study completedNCT00262002
What this trial is testing

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants

Who this might be right for
Prevention of Meningococcal Disease
Novartis Vaccines 601
Testing effectiveness (Phase 2)Study completedNCT00488683
What this trial is testing

B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

Who this might be right for
Meningococcal Disease
Novartis Vaccines 216
Large-scale testing (Phase 3)Study completedNCT00616421
What this trial is testing

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

Who this might be right for
Meningococcal Infections
Novartis Vaccines 2,907
Large-scale testing (Phase 3)Study completedNCT00944034
What this trial is testing

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis Vaccines 1,588
Large-scale testing (Phase 3)Study completedNCT00317109
What this trial is testing

Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 168
Large-scale testing (Phase 3)Study completedNCT01911221
What this trial is testing

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

Who this might be right for
Prevention of the Meningococcal Disease
Novartis Vaccines 13
Large-scale testing (Phase 3)Study completedNCT00311415
What this trial is testing

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children

Who this might be right for
Prevention of Meningococcal Infection
Novartis Vaccines 257
Testing effectiveness (Phase 2)Study completedNCT01434680
What this trial is testing

Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis 992
Large-scale testing (Phase 3)Active Not RecruitingNCT04415424
What this trial is testing

Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men

Who this might be right for
Neisseria Gonorrheae Infection
Kirby Institute 650
Testing effectiveness (Phase 2)Study completedNCT00721396
What this trial is testing

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules

Who this might be right for
Meningococcal Infections
Novartis Vaccines 1,885
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation